News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Tislelizumab plus chemotherapy in advanced gastric/GEJ adenocarcinoma
Photo from Miao-Zhen Qiu/LinkedIn
Jun 18, 2024, 07:07

Tislelizumab plus chemotherapy in advanced gastric/GEJ adenocarcinoma

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X:

“Tislelizumab plus chemotherapy vs chemotherapy alone in first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma.

RATIONALE-305

  • Median overall survival (mOS) in the intention-to-treat (ITT) population: 15 months versus 12.9 months, with a hazard ratio (HR) of 0.80 (95% CI 0.70 to 0.92); P=0.001.
  • Median overall survival (mOS) in the population with PD-L1 Tumor Proportion Score (TPS) ≥5%: 16.4 months versus 12.8 months, HR: 0.71 (95% CI 0.58 to 0.86).”

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Authors: Miao-Zhen Qiu, Do-Youn Oh, Ken Kato, Tobias Arkenau, Josep Tabernero, Marcia Cruz Correa, Anastasia V Zimina, Yuxian Bai, Jianhua Shi, Keun-Wook Lee, Jufeng Wang, Elena Poddubskaya, Hongming Pan, Sun Young Rha, Ruixing Zhang, Hidekazu Hirano, David Spigel, Kensei Yamaguchi, Yee Chao, Lucjan Wyrwicz, Umut Disel, Roberto Pazo Cid, Lorenzo Fornaro, Ludovic Evesque, Hongwei Wang, Yaling Xu, Jiang Li, Tao Sheng, Silu Yang, Liyun Li, Markus Moehler, and Rui-Hua Xu.

RATIONALE-305

Tislelizumab plus chemotherapy in advanced gastric/GEJ adenocarcinomaSource: Erman Akkus/X

Adenocarcinoma advanced gastric adenocarcinoma Anastasia V Zimina cancer chemotherapy David Spigel Do-Youn Oh Elena Poddubskaya Erman Akkus first-line treatment Gastroesophageal Junction Adenocarcinoma Hidekazu Hirano Hongming Pan Hongwei Wang Jiang Li Jianhua Shi Josep Tabernero Jufeng Wang Ken Kato Kensei Yamaguchi Keun-Wook Lee Liyun Li Lorenzo Fornaro Lucjan Wyrwicz Ludovic Evesque Marcia Cruz-Correa Markus Moehler median overall survival Miao-Zhen Qiu mOS OncoDaily Oncology RATIONALE-305 Roberto Pazo Cid Rui-Hua Xu Ruixing Zhang Silu Yang Sun Young Rha Tao Sheng Tislelizumab Tobias Arkenau Umut Disel Yaling Xu Yee Chao Yuxian Bai
Special Coverage
Insight
Dec 27, 2024, 17:53
The first round of chemotherapy in high-risk neuroblastoma patients - St. Baldrick's Foundation
Blog
Dec 27, 2024, 17:38
Long-Term Follow-Up and Overall Survival in NRG258 by Daniela E Matei et al.
Blog
Dec 27, 2024, 17:35
Rahul Gosain: CLL Highlights with John Allan
Insight
Dec 27, 2024, 17:30
Vivek Subbiah: An overview of AI methods designed to detect cancer early
Blog
Dec 27, 2024, 17:29
Almost all cancer treatments used in children today were actually developed for adults - Children's Cancer Institute
Blog
Dec 27, 2024, 17:27
Promising Efficacy and Controllable Safety of CD7 CAR-T Cell Therapy in Treating R/R PTCL - MediaMedic
Insight
Dec 27, 2024, 17:25
HTA recommendations on coverage and reimbursement for cancer medicines
Blog
Dec 27, 2024, 17:25
Habib Nehmé: Reflecting on the past and looking forward to the future
Blog
Dec 27, 2024, 17:16
Arif Kamal: The Hope Lodge Communities at ACS are a jewel in our crown
Blog
Dec 27, 2024, 17:13
Shilpa Gupta: Fortunate and blessed to work with such an amazing GU Oncology team at Cleveland Clinic
Science
Dec 27, 2024, 17:08
Colin Begg: Is it possible to conduct large randomized surgical clinical trials in a single institution?
Science
Dec 27, 2024, 17:06
Wafik S. El-Deiry: Pitfalls and perils from FDA-approved germ-line cancer predisposition tests